Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.
Key Metrics
EPS
8.52
Current ratio
0.99
Debt/Equity
1.21
Debt/EBITDA
7.49
Interest coverage ratio
0.39
Operating Cashflow to total debt
0.13
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Strong and diversified revenue streams
Healthy pipeline of biosimilar products
Sound operating capabilities
Average financial risk profile
Liquidity: Strong
Cons
Uncertainty regarding payoff in the R&D-driven model in the biosimilars business, especially in regulated markets
Susceptibility to regulatory changes and intense competition
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Biocon Limited bond.
This comprehensive profile covers key factual information about Biocon Limited. Biocon is engaged in the business of manufacture of biotechnology products and research services. EPS in Mar-2024 was 8.52. Current ratio in Mar-2024 was 0.99. Debt/Equity in Mar-2024 was 1.21. Debt/EBITDA in Mar-2024 was 7.49. Interest coverage ratio in Mar-2024 was 0.39. Operating Cashflow to total debt in Mar-2024 was 0.13. Total revenue for Mar-2025 (E) was ₹19,077.62. Net income for Mar-2025 (E) stood at ₹3,282.71. Total assets as of Mar-2024 were ₹55,753.40. Operating cash flow for Mar-2024 was ₹2,953.90. The company’s borrowing relationships include (₹N/A Cr), (₹N/A Cr), HDFC Bank Limited (₹N/A Cr). Peers and comparison entities consist of Biocon Limited, Panacea Biotec Limited, Hester Biosciences Limited, Zenotech Laboratories Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Strong and diversified revenue streams; Healthy pipeline of biosimilar products; Sound operating capabilities; Average financial risk profile; Liquidity: Strong. Key risks include: Uncertainty regarding payoff in the R&D-driven model in the biosimilars business, especially in regulated markets; Susceptibility to regulatory changes and intense competition. Leadership team details include Abhijit Zutshi (Chief Compliance Officer), Amit Kaptain (Head), Arun Gupta (Chief Operating Officer), Atul Dhawan (Independent Director), Bobby Kanubhai Parikh (Independent Director), Eric Vivek Mazumdar (Non Executive Non Independent Director), Kiran Mazumdar Shaw (Executive Chairperson), Maninder Kapoor Puri (Head - Human Resource), Manoj Kumar Pananchukunnath (Chief Scientific Officer), Mayank Verma (Company Secretary & Compliance Officer), Meleveetil Damodaran (Independent Director), Mukesh Kamath (Chief Financial Officer), Naina Lal Kidwai (Independent Director), Nicholas Robert Haggar (Independent Director), Nitin Tiwari (Head), Ravi Rasendra Mazumdar (Non Executive Non Independent Director), Rekha Mehrotra Menon (Independent Director), Siddharth Mittal (Managing Director & CEO), Vishal Nayyar (Head). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.